Medications targeting the neonatal fragment crystallizable receptor have gained attention due to multiple recent FDA ...
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results